ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
SpringWorks is in the air for Merck KGaA
The deal isn’t done, but would be Merck’s biggest oncology buy.
